The Food and Drug Administration has updated the labels on certain HIV drugs to include a contraindication for lurasidone (Latuda), an antipsychotic medication.
Lurasidone is used to treat depressive episodes in bipolar I disorder (bipolar depression) and schizophrenia in adults. The contraindication was added because of “the potential for serious and/or life-threatening reactions,” according to the FDA.
The labels on the following pharmaceutical products will be updated to reflect the change:
Aptivus (tipranavir)
Crixivan (indinavir)
Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide)
Invirase (saquinavir)
Kaletra (lopinavir/ritonavir)
Lexiva (fosamprenavir): Lurasidone is contraindicated because of the potential for serious and/or life-threatening reactions if fosamprenavir is coadministered with ritonavir.
Norvir (ritonavir)
Prezista (darunavir)
Reyataz (atazanavir): Lurasidone is contraindicated because of the potential for serious and/or life-threatening reactions if atazanavir is coadministered with ritonavir.
Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)
Viracept (nelfinavir)
Labels for Evotaz (atazanavir/cobicistat) and Prezcobix (darunavir/cobicistat) already include a contraindication for lurasidone, the FDA announcement noted.
On Twitter @richpizzi
